Relapsed Refractory Multiple Myeloma (RRMM)

Oncology
3
Pipeline Programs
2
Companies
6
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
1
LinvoseltamabPhase 3Monoclonal Antibody5 trials
LinvoseltamabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT07455851Not Yet Recruiting150Est. Sep 2033
NCT07428369Not Yet Recruiting1,570Est. May 2038
NCT07393282Not Yet Recruiting270Est. Jul 2033
+3 more trials
Sanofi
SanofiPARIS, France
1 program
1
elranatamabPhase 2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
RegeneronLinvoseltamab
RegeneronLinvoseltamab
RegeneronLinvoseltamab
RegeneronLinvoseltamab
RegeneronLinvoseltamab
RegeneronLinvoseltamab

Clinical Trials (6)

Total enrollment: 3,343 patients across 6 trials

NCT07393282RegeneronLinvoseltamab

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Start: Mar 2026Est. completion: Jul 2033270 patients
Phase 3Not Yet Recruiting
NCT07222761RegeneronLinvoseltamab

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Start: Jan 2026Est. completion: Sep 2034915 patients
Phase 3Recruiting
NCT05730036RegeneronLinvoseltamab

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Start: Sep 2023Est. completion: Apr 2033410 patients
Phase 3Recruiting
NCT07428369RegeneronLinvoseltamab

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Start: Jun 2026Est. completion: May 20381,570 patients
Phase 2/3Not Yet Recruiting
NCT06376526RegeneronLinvoseltamab

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Start: Aug 2024Est. completion: Aug 202928 patients
Phase 2Recruiting
NCT07455851RegeneronLinvoseltamab

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Start: Mar 2026Est. completion: Sep 2033150 patients
Phase 1/2Not Yet Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 3,343 patients
2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)